A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
NCT ID: NCT07325136
Last Updated: 2026-01-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1/PHASE2
240 participants
INTERVENTIONAL
2026-02-18
2029-04-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BMS-986012 in Relapsed/Refractory SCLC
NCT02247349
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
NCT05005273
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT06094296
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
NCT00461110
Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens
NCT01721759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1A: BMS-986525 Monotherapy Dose Escalation
BMS-986525
Specified dose on specified days
Part 1B: BMS-986525 Combination with Nivolumab Dose Escalation
BMS-986525
Specified dose on specified days
Nivolumab
Specified dose on specified days
Part 2A: BMS-986525 Monotherapy Dose Expansion
BMS-986525
Specified dose on specified days
Part 2B: BMS-986525 Combination with Nivolumab Dose Expansion
BMS-986525
Specified dose on specified days
Nivolumab
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-986525
Specified dose on specified days
Nivolumab
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
* In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.
Exclusion Criteria
* Participants must not have an active, known or suspected autoimmune disease.
* Participants must not have had a prior organ or tissue allograft.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 0011
Detroit, Michigan, United States
Local Institution - 0026
Buffalo, New York, United States
Local Institution - 0005
Durham, North Carolina, United States
Local Institution - 0004
Cleveland, Ohio, United States
Local Institution - 0006
Nashville, Tennessee, United States
Local Institution - 0001
Rozzano, Milano, Italy
Local Institution - 0020
Hirakata, Osaka, Japan
Local Institution - 0018
Chuo-ku, Tokyo, Japan
Local Institution - 0023
Timișoara, Timiș County, Romania
Local Institution - 0003
Craiova, , Romania
Local Institution - 0009
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Role: CONTACT
First line of the email MUST contain the NCT# and Site#
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 0011
Role: primary
Site 0026
Role: primary
Site 0005
Role: primary
Site 0004
Role: primary
Site 0006
Role: primary
Site 0001
Role: primary
Site 0020
Role: primary
Site 0018
Role: primary
Site 0023
Role: primary
Site 0003
Role: primary
Site 0009
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-524090-16
Identifier Type: OTHER
Identifier Source: secondary_id
CA258-0001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.